{"product_id":"torch-panel-rapid-test","title":"TORCH Panel Rapid Test","description":"\u003cp\u003e\u003cstrong\u003eProduct Features\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cul\u003e\n\u003cli\u003eDistinguishes between IgG and IgM in all five TORCH infections\u003c\/li\u003e\n\u003cli\u003eCompatible with serum, plasma, and whole blood\u003c\/li\u003e\n\u003cli\u003eResults available in 15 minutes\u003c\/li\u003e\n\u003cli\u003eProvides semi-quantitative results for Rubella IgG antibodies\u003c\/li\u003e\n\u003cli\u003eDistinguishes between HSV-1 and HSV-2\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eShelf life: \u003c\/strong\u003e18 months\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAnalytical Sensitivity of IgG Detection: \u003c\/strong\u003eTwenty negative specimens were spiked with appropriate reference standards at various concentrations. Specimens were run on the \u003cem\u003eOnSite\u003c\/em\u003e TORCH Panel Rapid Test panel member. Defined as the 95% detection level, the limits of detection, or sensitivity, were determined to be as follows:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cstrong\u003eToxo: \u003c\/strong\u003e5 IU\/mL LOD; WHO International Standard Anti-Toxoplasma Serum Ig (TOXM)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRubella:\u003c\/strong\u003e 15 IU\/mL (G1); 250 IU\/mL (G2); WHO 1\u003csup\u003est\u003c\/sup\u003e International Standard (RUBI-1-94)\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eAccuracy of IgG Detection in comparison with commercial ELISA: \u003c\/strong\u003eClinical IgG positive specimens were collected and tested on each \u003cem\u003eOnSite\u003c\/em\u003e TORCH Panel Rapid Test panel member as well as by commercial ELISA. Comparison for all subjects showed the following overall agreements:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003col\u003e\n\u003cli\u003e\u003cstrong\u003eToxo (237 specimens): 94.9%\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eRubella (214 specimens): 97.7%\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eCMV (258 specimens): 93.4%\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eHSV-1 (227 specimens): 90.7%\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eHSV-2 (214 specimens): 95.3%\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eAccuracy of IgM Detection in comparison with commercial ELISA: \u003c\/strong\u003eClinical IgM positive specimens  were collected and tested on each \u003cem\u003eOnSite\u003c\/em\u003e TORCH Panel Rapid Test  panel  member  as  well  as  by  commercial    Comparison  for  all  subjects  showed  the following overall agreements:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003col\u003e\n\u003cli\u003e\u003cstrong\u003eToxo (231 specimens): 98.8%\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eRubella (25 specimens): 96.0%\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eCMV (212 specimens): 93.9%\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eHSV-1 (107 specimens): 85.0%\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eHSV-2 (26 specimens): 95.2%\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eCross Reactivity:\u003c\/strong\u003e No false positive IgG and IgM results were observed on 3-14 specimens from the following disease states or special conditions, respectively: Toxo, Rubella, CMV, HSV-1, HSV-2, hCG, HAV, HBV, HCV, HEV, HIV, TB, \u003cem\u003epalladium\u003c\/em\u003e, Dengue, Malaria, \u003cem\u003eH. pylori, \u003c\/em\u003eTyphoid, ANA, HAMA, and RF (\u0026gt;1,000 IU\/mL).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch6\u003e\n\u003cem\u003eDuring cross-reactivity testing for each TORCH infection, self-reactivity was not considered (i.e. rubella positive samples were not tested on the Rubella IgG\/IgM Rapid Test). Specimens tested vary for each panel member of the OnSite TORCH \u003c\/em\u003e\u003cem\u003ePanel \u003c\/em\u003e\u003cem\u003eRapid Test.\u003c\/em\u003e\n\u003c\/h6\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eInterference:\u003c\/strong\u003e No interference was seen from the following substances: Albumin 60 g\/L; Bilirubin 20 mg\/dL; Heparin 3,000 U\/L; Hemoglobin 2 g\/L; Creatinine 442 µmol\/L; EDTA 3.4 µmol\/L; Salicylic acid 4.34 mmol\/L; Glucose 55 mmol\/L; and Sodium citrate 3.8%.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eProduct specifications\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eIndividually sealed foil pouches containing:\n\u003cul\u003e\n\u003cli\u003eOne cassette device\u003c\/li\u003e\n\u003cli\u003eTwo desiccants\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003ePlastic droppers\u003c\/li\u003e\n\u003cli\u003eSample diluent (REF SB-R0253, 5 mL\/bottle)\u003c\/li\u003e\n\u003cli\u003eOne package insert (instruction for use)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eSupport\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/drive.google.com\/open?id=1mDPmFTPbRq-pecdxkRdno5tH6cCgspil\"\u003eCTK Products at a Glance\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/ctkbiotech.com\/support\/technical-information\/\" target=\"_blank\" rel=\"noopener\"\u003eInserts\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/drive.google.com\/open?id=1rVsFp3e7U_sIUgcVJajRe7iK0ZXEzTsW\"\u003eFlyer\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/ctkbiotech.com\/support\/technical-information\/\"\u003eOnSite ToRCH Panel Rapid Test Training Presentation\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\n\u003cdiv class=\"woocommerce-tabs wc-tabs-wrapper\"\u003e\n\u003cp\u003eThe \u003cem\u003eOnSite \u003c\/em\u003eTORCH Panel Rapid Test is a lateral flow chromatographic immunoassay for the qualitative detection and differentiation of antibodies (IgG and IgM) to Toxoplasma gondii (T. gondii), rubella virus, cytomegalovirus (CMV), herpes simplex virus 1 (HSV-1), and herpes simplex virus 2 (HSV-2) in human serum, plasma, or whole blood.\u003c\/p\u003e\n\u003cp\u003eThis test is intended to be used by professionals as a screening test and provides a preliminary test result to aid in the diagnosis of infection with \u003cem\u003eT. gondii\u003c\/em\u003e, rubella virus, CMV, HSV-1 and HSV-2. Any interpretation or use of this preliminary test result must also rely on other clinical findings as well as on the professional judgment of health care providers. Alternative test method(s) should be considered to confirm the test result obtained by this device.\u003c\/p\u003e\n\u003cp\u003eRecommended for use:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAny person presenting with clinical signs or symptoms consistent with TORCH infection.\u003c\/li\u003e\n\u003cli\u003eWomen who are pregnant or who are planning to become pregnant\u003c\/li\u003e\n\u003cli\u003eIndividuals with a compromised immune system\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe \u003cem\u003eOnSite\u003c\/em\u003e TORCH Panel Rapid Test detects and differentiates IgG and IgM antibodies for all 5 TORCH infections. In general, a negative test result indicates that the individual is at risk for acquiring a primary infection. A positive IgM result only indicates acute infection, a positive IgM and IgG test indicate acute, late phase infection, and a positive IgG test result only indicates past or chronic infection.\u003c\/p\u003e\n\u003cp\u003eThe presence of IgM anti-rubella virus or high titers of IgG anti-rubella virus (\u0026gt; 200 IU\/mL) are suggestive of acute rubella infection. Lower titers of IgG anti-rubella virus (≥ 10-15 IU\/mL) are suggestive of previous exposure and protective immunity. An individual with an IgG anti-rubella virus titer less than 10-15 IU\/mL is considered to be at risk of acquiring a rubella virus infection.\u003c\/p\u003e\n\u003cp\u003eThe TORCH Panel Rapid test also differentiates between HSV-1 and HSV-2 antibodies using HSV-1 specific glycoprotein G1 and HSV-2 specific glycoprotein G2.\u003c\/p\u003e\n\u003c\/div\u003e\n","brand":"I-Surgical","offers":[{"title":"Default Title","offer_id":45377588035631,"sku":null,"price":100.0,"currency_code":"NAD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0764\/9964\/8559\/files\/9086_r0253c-whole-package-1.png?v=1779383262","url":"https:\/\/i-surgical.com\/products\/torch-panel-rapid-test","provider":"I-Surgical","version":"1.0","type":"link"}